Enhancing HIV vaccine responses by targeting natural killer cells

Targeting natural killer cells to enhance HIV vaccine responses

NIH-funded research Cincinnati Childrens Hosp Med Ctr · NIH-10656405

This study is looking at how certain immune cells called natural killer (NK) cells influence the body's response to HIV vaccines, with the goal of finding ways to make these vaccines work better for people by boosting the production of protective antibodies.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionCincinnati Childrens Hosp Med Ctr NIH-funded
Lab location1 site (Cincinnati, United States)
Project IDNIH-10656405 on NIH RePORTER

What this research studies

This research investigates how natural killer (NK) cells affect the immune response to HIV vaccines. It aims to understand the mechanisms by which NK cells suppress the production of protective antibodies, which are crucial for preventing HIV infection. By targeting these NK cells, the study seeks to improve the effectiveness of HIV vaccines, potentially leading to better immune responses in vaccinated individuals. The research involves both laboratory experiments and translational approaches to overcome immune regulatory barriers.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals at risk of HIV infection who are interested in participating in vaccine trials.

Not a fit: Patients who are already HIV positive or those who have contraindications to vaccination may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to more effective HIV vaccines that generate stronger and longer-lasting immune responses.

How similar studies have performed: Previous research has shown promise in enhancing vaccine responses by targeting immune cells, suggesting that this approach could be effective.

Where this research is happening

Cincinnati, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.